A Trypanosoma cruzi Xgtll cDNA clone, JL5, expressed a recombinant protein which was found to react predominantly with chronic Chagas' heart disease sera. The cloned 35-residue-long peptide was identified as the carboxyl-terminal portion of a T. cruzi ribosomal P protein. The JL5 13 carboxyl-terminal residues shared a high degree of homology with the systemic lupus erythematosus (SLE) ribosomal P protein epitope. Synthetic peptides comprising the 13 (R-13), 10 (R-10), and 7 (R-7) carboxyl-terminal residues of the JL5 protein were used to study, by enzyme-linked immunosorbent assay, the specificity of the Chagas' disease anti-JL5 and SLE anti-P antibodies. The R-13 peptide defined a linear antigenic determinant of the JL5 recombinant protein. As was proved for JL5, R-13 defined antibody specificities which were significantly increased in chronic Chagas' heart disease patients. Only SLE anti-P positive sera were found to react with JL5 and R-13. Fine epitope mapping showed that Chagas' disease anti-JL5 and SLE anti-P antibodies define similar epitopes within the R-13 peptide. The binding of the SLE sera to JL5 was completely blocked by the R-13 peptide, indicating that the shared specificity between anti-JL5 and anti-P autoantibodies was exclusively limited to the conserved linear epitope(s) within the R-13 peptide.
anti-P antibodies. The R-13 peptide defined a linear antigenic determinant of the JL5 recombinant protein. As was proved for JL5, R-13 defined antibody specificities which were significantly increased in chronic Chagas' heart disease patients. Only SLE anti-P positive sera were found to react with JL5 and R-13. Fine epitope mapping showed that Chagas' disease anti-JL5 and SLE anti-P antibodies define similar epitopes within the R-13 peptide. The binding of the SLE sera to JL5 was completely blocked by the R-13 peptide, indicating that the shared specificity between anti-JL5 and anti-P autoantibodies was exclusively limited to the conserved linear epitope(s) within the R-13 peptide. The prevalence of high anti-R-13 antibody titers in Chagas' heart disease patients supports the hypothesis that postulates the existence of autoimmune disorders in Chagas' heart disease.
Chagas' disease, caused by the hemoflagellate Trypanosoma cruzi, is a widespread tropical disease affecting most Latin American countries. The acute period of the infection lasts 1 or 2 months and is usually symptomless. It can be estimated that more than 90% of the infected individuals enter the chronic period of infection and can develop the illness without warning (8) .
Most of the chronically infected individuals never show discernible evidence of the disease, in spite of the fact that the infection persists throughout life. A variable percentage, up to 30%, with strong regional differences, develops symptoms of visceral damage. The ability to diagnose these symptoms early is lacking at present.
The most frequent clinical manifestation of the disease is the development of a panmyocarditis, which is anatomically expressed by myocardial damage associated to mononuclear inflammatory foci scattered throughout the heart (8) . The coexistence of areas of myocytic degeneration, inflammatory infiltration, and fibrosis suggests a chronically evolving process. Since the intracellular forms of the parasite are rarely found in chagasic myocarditis, the hypothesis of an autoimmune process has been proposed (8, 16, 23, 27) .
In terms of the human humoral response, several authors have described the existence of circulating antibodies against different self antigens (23, 26, 27, 29, 32) . However, no link between these antibodies and chagasic pathology has been firmly established (17, 27) .
In a recent attempt to identify parasite antigens defined by * Corresponding author.
sera from subjects with chronic Chagas' heart disease (cChHD), a T. cruzi Xgtll recombinant antigen, JL5, was characterized that reacted predominantly with sera from this group of patients (20) . The antigenic determinant of the JL5 recombinant was a small 35-amino-acid peptide. The nucleotide and the deduced amino acid sequence, together with other experimental data, allowed identification of this peptide as the carboxyl-terminal portion of a T. cruzi ribosomal P protein. The carboxyl-terminal undecapeptide in JL5, EDDDMGFGLFD, was highly homologous to the same region of the human P proteins, SD(EID)DMGFGLFD (24) . The latter sequence has been identified as the P protein epitope in systemic lupus erythematosus (SLE) (10, 11) . In this report, we have attempted to map the main antigenic region of the T. cruzi ribosomal P protein encoded by the JL5 recombinant and to compare it with the known SLE P protein autoepitope. Synthetic peptides comprising the 13, 10, and 7 carboxyl-terminal residues of JL5 protein were used to study, by enzyme-linked immunosorbent assay (ELISA), the specificity of the Chagas' disease anti-JL5 and SLE anti-P antibodies and to map the epitopes defined by them. In addition, the titer of circulating antibodies to the JL5 P-galactosidase (,-gal) fusion protein and to the synthetic peptides was measured both in cChHD sera and in sera from chronically infected subjects presenting no clinical evidence of heart damage. 
RESULTS
The carboxyl-terminal portion of the T. cruzi ribosomal P protein encoded by the JL5 recombinant peptide is represented in Fig. 1 . The hydrophilicity plot reveals an alaninerich hydrophobic region, ranging from residues 1 to 21, and a hydrophilic carboxyl-terminal peptide, ranging from residue 22 to the final aspartic acid residue. The cloned T. cruzi ribosomal P protein sequence is compared with the corresponding sequences from Saccharomyces cerevisiae (15) , Artemia salina eL12 and eLl2' (1, 2), rat (21) , and human ribosomal P proteins Pi, P2, and PO (24) (Fig. 2) . The T. cruzi 13-carboxyl-terminal-amino-acid sequence shares more than 90% homology with the human ones. To verify whether this conserved, hydrophilic portion of the parasite ribosomal P protein was involved in the immunological reaction with chagasic sera, a 13-amino-acid peptide was synthesized (R-13; Fig. 2B ). This peptide was compared with the JL5 recombinant fusion protein for their ability to react with sera from clinically characterized T. cruzi-infected individuals. Twelve SLE serum samples (among them, six anti-P positive serum samples) were included in the assays to allow comparisons between P positive sera from parasite-infected and noninfected subjects.
As shown in Tables 1 and 2 and Fig. 3 Amino acid sequence and hydrophilicity plot of the carboxyl-terminal portion of the T. cruzi ribosomal P protein encoded by recombinant JL5, as described by Kyte and Doolittle (18) . The calculation was done by using the HYDRPHIL program (31) . The dashed line corresponds to the carboxyl-terminal hydrophilic region (underscored residues).
failed to react with the R-13 peptide, a significant correlation between anti-R-13 and anti-JL5 reactivities was found (r = 0.7; P < 0.05), indicating that the R-13 peptide defines a linear antigenic region of the JL5 recombinant protein involved in the immunoreactivity with cChHD sera. Sera from normal, noninfected individuals and from patients with nonchagasic idiopathic dilated cardiomyopathy failed to react with R-13 and JL5 (Table 1) . Only the six anti-P positive SLE serum samples were found to react with R-13 and JL5, indicating that both T. cruzi peptides contained sequences recognized by anti-human P protein antibodies.
To determine the fine specificity of the anti-R-13 antibodies from cChHD sera and to compare it with that of SLE anti-P antibodies, the binding of the antibodies to the synthetic peptides R-7 and R-10 was analyzed by ELISA (Fig.  2B) . Most cChHD sera presented a similar reactivity to the R-7 and the R-10 peptides (Table 1 ; Fig. 4 ). These reactivities were always lower than the anti-R-13 reactivities. The results suggested that the three glutamic residues were critical in determining the immunological reactivity of the R-13 epitope. The reactivity of 6 out of 13 cChHD serum samples (Table 1) with the R-10 and R-7 peptides (Hi and H4 in Fig. 4A ) revealed the existence of another epitope located within the seven carboxyl-terminal residues.
Three out of six anti-P positive SLE serum samples showed similar antibody titers to the three terminal peptides (Table 1 ; Fig. 4 , serum Si). The other three showed an anti-R-13, anti-R-10, and anti-R-7 profile reminiscent of that observed for cChHD sera (Table 1 ; Fig. 4C, serum S4 ). The specificity of the anti-R-13 reaction was verified by ELISA inhibition experiments in which R-7, R-10, and R-13 peptides were used to inhibit the binding to R-13. The inhibition experiments are in agreement with the direct binding assays (Fig. 5) .
To define the specificity of cChHD and SLE antibodies to the cloned portion of the T. cruzi P protein, the inhibition of the ELISA reaction between recombinant JL5 and anti-P antibodies by the three carboxyl-terminal peptides was studied. Results in Fig. 6A and B showed that only a partial inhibition was obtained for cChHD sera. On the contrary, the two SLE serum samples studied were almost completely inhibited by the R-13 peptide (Fig. 6C and D) , indicating that this anti-P protein reactivity was only directed to the conserved carboxyl-terminal epitope of T. cruzi JL5.
DISCUSSION
The ELISA measurements allowed us to quantify the immunological response of chagasic sera to the carboxylterminal portion of the T. cruzi ribosomal P protein encoded A.
B.
ASAPTAAAAASGGAAAPAAAA ........... EEEEDDDMGFGLFD +G*S+*+P*++*+**+G+D** .... EEKEEEAK**S********** +GVGA*P**+G++**TE*P**K^EEKKEEKKEES****+******** PT+GAP*** *G*+** * ** *E *XEAXKEEXKEES* ** *+* ** ** ** * P++GAV*V+*+P*******++APAAAEE.KEES**IKU*+******* V+VSA+P++*+P+*++AP***.EEKKDEKKEES**S********** *P*AG**P*+GP+P+TA**V*EEKKVEAKKEES**S********** V+*APV***T+++P**A**P*.... KVEAKEES**S*+******** A. salina H. sapiens H. sapiens (24) . Sequence homology with respect to JL5 is indicated with asterisks and plus signs indicate conservative amino acid changes, so that T and S, D and E, A and S, and A and G are considered to be homologous pairs. (B) Amino acid sequence comparison of carboxyl-terminal synthetic peptides of T. cruzi JL5 and the human (H. sapiens) and A. salina 13 terminal residues; underscored residues define the reported SLE ribosomal P epitope (10). by the JL5 recombinant. All T. cruzi-infected individuals had a positive anti-JL5 antibody titer, exceeding several times the absorbance values observed for normal controls. A significant correlation between high anti-JL5 antibody titers and cChHD was found, confirming previous results (20) . The linear antigenic determinant of JL5 was predicted to lie in the carboxyl-terminal end, as was the case for the SLE cChHD serum epitope mapping with R-13, R-10, and R-7 suggested the existence of at least two epitopes, one contained within the seven carboxyl-terminal residues and the other one present in R-13 but not in R-10. These two epitopes were also mapped by SLE anti-P antibodies.
The ability of the R-13 peptide to completely inhibit the reactivity of SLE anti-P antibodies to the JL5 recombinant protein proved that the specificity shared between SLE anti-P antibodies and cChHD anti-JL5 antibodies was con- tained in the R-13 peptide. Its amino acid sequence defined the Chagas and SLE anti-P antibody specificity.
In addition to the identification of this shared sequential determinant, the fact that synthetic peptides did not completely inhibit the reaction between the JL5 and cChHD sera revealed the existence of either conformational or sequential epitopes in the JL5 recombinant protein that are specific for the T. cruzi infection (Fig. 6A and B) . These observations suggested that only a variable percentage of the total cChHD anti-JL5 reactivities (from 20 to 40%, depending on the serum sample) would be able to cross-react with the ribosomal P proteins of the host. As predicted and in accordance with the statements above, when anti-JL5 antibodies, immunoselected from different cChHD sera, were tested for antihuman ribosome reactivity by immunoblotting, the intensity of the reaction with the three ribosomal P proteins (PO, Pi, and P2) varied depending on each serum anti-R13 antibody titer (G. Levitus, M. Hontebeyrie-Joskowicz, and M. J. Levin, submitted for publication).
Anti-P antibodies in Chagas' disease may be induced by the presence of cross-reactive epitopes in the parasite (molecular mimicry). However, it is intriguing that in other chronic parasitic infections such as malaria, anti-P antibodies could not be detected (6) , although Plasmodium falciparum has been shown to possess ribosomal P proteins that react with SLE anti-P antibodies (12) . While our findings suggest the possible role of molecular mimicry in the induction of anti-P antibodies, other autoimmune mechanisms known to occur during chronic T. cruzi infection, such as polyclonal B-and T-cell activation (9, 16, 23) and development of cell-mediated immunity against host antigens (13, 16, 19, 23), may operate alone or in association and may contribute to generate the chagasic anti-P response.
As described for autoimmune diseases, various parasitic and bacterial infections are associated with the induction of autoantibodies to intracellular antigenic determinants (3, 6, 28) . Antinuclear antibodies, for example, a hallmark of SLE, have been reported to be present in malaria and leprosy (6) . On the contrary, they were not detected in the chagasic sera used in this study (see Materials and Methods). Nevertheless, our results show that autoantibodies with a similar specificity to those found in SLE do indeed exist in Chagas' disease. The anti-P antibody specificity is the first autoantibody common to SLE and Chagas' disease that has been characterized. Anti-P antibodies have been particularly associated with lupus psychosis (5) and were also found in sera from SLE patients with cardiovascular and muscular involvement (4). It is thus remarkable that, for T. cruziinfected subjects, the highest anti-P antibody titers correspond to cChHD patients.
So far there is no evidence about the role, if any, of anti-P antibodies in the pathology of Chagas' disease. Of interest, however, is the observation that immunization of mice with ribosomal T. cruzi antigens induced an intense myocarditis compatible with an anti-self, organ-specific, immunologic response (25) .
The results herein support the hypothesis that postulates the existence of autoimmune disorders in cChHD. We further suggest that the study of anti-P antibody induction during T. cruzi infection may provide some clues as to the origin of anti-P antibodies in SLE.
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